News and Press Releases

Presbyopia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Presbyopia is an age-related eye condition that causes visual impairment gradually. With the onset age of 40 years, presbyopia results in the loss of flexibility of the eye to visualize nearly placed objects.

Approval of Late-Stage Pipeline Products to Drive the Growth of Overall Retinitis Pigmentosa (RP) Therapeutics Pipeline and Approved Drugs Market

According to a new research report “Retinitis Pigmentosa Therapeutics – Pipeline Analysis, Epidemiology and Drug Forecasting” published by Pharma Proff, retinitis pigmentosa (RP) therapeutics currently exhibits a proliferating pipeline of 18 emerging therapies and one marketed product.

Bromodomain and Extraterminal Domain (BET) Inhibitors Pipeline to Witness Significant Growth Due to High Potential of the Market in the Coming Years

BET proteins are epigenetic readers characterized by the presence of two tandem bromodomains (BD1 and BD2), extraterminal domain (ET), and a C-terminal domain (CTD). Moreover, these proteins also recognize acetylated nonhistone proteins, including different transcription factors.

Cyclin-Dependent Kinase (CDK) Inhibitors Pipeline to Witness Significant Growth Due to High Potential of the Market in the Coming Years

CDKs are protein kinases that require a separate subunit – a cyclin – which provides domains essential for enzymatic activity. The CDK family can be categorized into three cell-cycle-related subfamilies (CDK1, CDK4, and CDK5) and five transcriptional subfamilies (CDK7, CDK8, CDK9, CDK11, and CDK20).

Allergy Immunotherapy Pipeline to Witness Significant Growth Due to Entry of Various Short-Course Therapies

Allergic diseases occur as a result of reaction of the body’s immune system with certain foreign substances, known as allergens, such as house dust mites (HDM), some food products (peanut, egg, milk and shellfish), pollen (grass, ragweed, and birch), and insect bites and stings (bee venom).

Oral Mucositis (OM) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

OM is an inflammation of the oral mucosa, which is a common side-effect of chemotherapy and radiotherapy. The inflammation leads to the formation of ulcers and infections in mouth.

Mitochondrial-Based Therapeutics Pipeline to Observe Significant Growth in the Coming Years due to Booming Strategic Developments

Mitochondria generate adenosine tri-phosphate (ATP) through oxidative phosphorylation, and also plays a key role in apoptosis. Mitochondrial therapeutic development is focused on diseases, which are caused by mutations in mitochondrial deoxyribonucleic acid (DNA) or in nuclear gene encoding mitochondrial protein.

β-Site Aβ Cleaving Enzyme or Beta-Secretase (BACE) Inhibitors Pipeline to Propel with Increasing Number of Players

BACE is a cleaving enzyme that acts as a precursor of BACE α-amyloid (Aβ) protein generation. It possesses BACE α-secretase activity and is important for the formation of myelin sheaths in peripheral nerve cells. BACE can be classified into BACE1 and BACE2.

Systemic Lupus Erythematosus (SLE) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation of cartilage and blood vessels. Pain and swelling in joints, sensitivity to sun, unexplained fever, joints and muscle pain, mouth ulcers, swollen glands, and others are some common symptoms of the disease.

T-Cell Immunotherapy Pipeline to Witness Significant Growth due to Increase in Designation Granted by Regulatory Authorities

T-cell immunotherapy consists of T-cell receptor (TCR), tumor-infiltrating lymphocyte (TIL), and chimeric antigen receptor (CAR) T-cell therapy. TCR is an integral membrane protein that is activated by major histocompatibility complex (MHC) molecules in the presence of an antigen.

Urinary Tract Infection (UTI) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

UTI is an infection caused in any part of the urinary tract including urethra, ureter, bladder, and kidney. This may happen due to the invasion of bacteria causing infection, which spreads from large intestine to anus.

Cushing’s Syndrome Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Overproduction of cortisol hormone leads to Cushing’s syndrome. Also, exposure to glucocorticoids is expected to be one of the prime causes of the disease.

Rising Clinical Trial Results to Cater the Growth of Sarcopenia Therapeutics Pipeline

Sarcopenia is a disease related to muscle loss, due to the natural aging process. The disease aggravates after 70 years of age. Loss of muscle and body strength affects the overall balance and ability to perform day-to-day tasks of a person.

Adrenoleukodystrophy (ALD) Therapeutics Pipeline to Witness Significant Growth in the Coming Years due to Increasing Strategic Developments

ALD is a X-linked genetic disease which falls under the family of leukodystrophies disorder. The disease is monogenetically inherited from parents to offspring, with 100% penetrance in men and 65% in heterozygous women.

Various Strategic Advancements in Drug Development are Beholding the Growth of Peanut Allergy Therapeutics Pipeline

Peanuts can cause a severe life-threatening allergic reaction, which is referred to as peanut allergy. This type of allergy is one of the most common cause of food allergy, which occurs when immune system reacts to protein found in peanuts.

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline to Witness Significant Growth due to Increase in the Designation Grants Provided by Regulatory Authorities in the Coming Years

Phosphatidylinositol 3-kinase (PI3K) belongs to lipid kinases and plays a vital role in cell signaling. It is an intermediate molecule in mTOR/AKT/PI3K signaling cascade.

Various Advancements in Drug Development Technologies are Beholding the Growth of Rectal Cancer Therapeutics Pipeline

Rectal cancer, also known as colon cancer, bowel cancer, or colorectal cancer, is the growth of malignant and cancerous cells in the lower part of the colon.

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by Staphylococcus staph) bacteria, which are resistant to several antibiotics. The staph bacteria are naturally present in nose and on skin, but do not cause any harm.

Mechanistic Target of Rapamycin (mTOR) Inhibitors Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Mechanistic target of rapamycin (mTOR) is a serine and threonine protein kinase that is considered as a target for immunosuppressive drug rapamycin and is present in two distinct complexes.

Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant Growth due to Increasing Strategic Developments in the Coming Years

Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease.

HSV and HPV Infections Epidemiology to Witness Burgeoning Trends in the Coming Years

HPV is a group of more than 200 related viruses, which spreads mostly through anal, oral, and vaginal sex. The sexually transmitted HPV infections are categorized into two groups: low-grade, and high-grade HPVs.

Acute Kidney Injury (AKI) Therapeutics to Witness Significant Growth due to Positive Clinical Results in the Coming Years

AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system.

Alzheimer’s Disease Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Advanced Regulatory Approaches by Drug Developers

Alzheimer’s disease is an irreversible brain disorder caused due to degradation of cells and tissues in the brain. The progressive disorder slowly destroys memory, thinking, social, and behavioral skills.

Candidiasis Therapeutics to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Candidiasis is the most common yeast infection caused by Candida spp. that exist both as a commensal and pathogen. Candida albicans is generally considered as the most pathogenic member of the genus and most common cause of different types of candidiasis.

Hereditary Angioedema (HAE) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

HAE is a genetic disease that results in swelling under the skin, lining of guts and lungs. Symptoms of the disease usually occur in childhood, and get aggravated in teenage.

Spinal Muscular Atrophy (SMA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Spinal muscular atrophy (SMA) is a rare inherited genetic disease that is characterized by loss of nerve cells, known as motor neurons.

Psoriasis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Psoriasis is identified as a condition which causes chronic inflammation and scaling on skin. It develops when skin cells grow rapidly below the surface of the skin and get deposited on the surface before they get matured.

Retinitis Pigmentosa (RP) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP.

Drug Designations to Boost the Rhabdomyosarcoma (RMS) Therapeutics Development

Rhabdomyosarcoma (RMS) is a type of cancer that usually affects children. Soft tissues or hollow organs such as bladder or uterus are often affected by this disease. There are mainly two types of RMS: embryonal RMS (ERMS) and alveolar RMS (ARMS).

Synovial Sarcoma Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Synovial sarcoma is a soft-tissue sarcoma, which is divided into four stages (I, II, III, and IV) depending on the size of tumor. The growth of the tumor tends to cause numbness and pain in joints when it presses against nerves.

Ulcerative Colitis (UC) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Ulcerative colitis (UC) is a disease that affects colon or large intestine and results in inflammation of the colon and development of ulcers on intestinal linings. The disease is a result of improper functioning of immune system.

Positive Clinical Trials Mark the Growth of Pancreatic Cancer Therapeutics Pipeline

Pancreatic cancer occurs due to the formation of malignant cells in the pancreas which eventually leads to the development of tumors. Tumors are further classified into exocrine tumor and endocrine tumor.

Adoption of Advanced Regulatory Approaches by Drug Developers to Mark the Growth in Pancreatic Cancer Therapeutics Pipeline

Pancreatic cancer is identified as the formation of tumor due to development of malignant cells in the pancreas. There are two main forms of the disease, namely endocrine and exocrine tumors.

Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Friedreich’s ataxia (FRDA) is an inherited autosomal recessive genetic condition that progressively damages the nervous system, with a typical age of onset between 10 years and 15 years.

Post-Operative Pain Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Post-operative pain is a very common problem experienced by patients who undergo surgical procedures. Pain is an unpleasant sensory and emotional experience caused by any injury, disease, or surgical procedure.

Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Post-Traumatic Stress Disorder (PTSD) is a serious condition that occurs in people who have experienced or witnessed a life-threatening event, such as a natural disaster, serious accident, terrorist incident, sudden death of a loved one, war, rape, or other violent personal assault.

Prostatitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Prostatitis refers to a group of disorders that lead to inflammatory condition causing pain in prostate gland. The disease is categorized into four forms: chronic pelvic pain syndrome (CPPS), acute bacterial prostatitis, chronic bacterial prostatitis, and asymptomatic prostatitis.

Strategic Advancements in Drug Development are Beholding the Growth of Proteasome Inhibitors Pipeline

Proteasomes are small, barrel-formed structures found in cells having a function of degrading the misfolded and non-useful proteins inside the cells. Proteasome inhibitors focus on proteasomes in the disease cells and hinder their action by binding to them.

Neurofibromatosis (NF) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Neurofibromatosis (NF) is a genetic disorder that causes tumors on nerve tissues. These are usually non-cancerous, but few can be developed into cancer. The disorder becomes prominent by the age of 10–15 years.

Strategic Advancements in Drug Development are Beholding the Growth of OX40 Receptor Agonists Pipeline

OX40 receptor holds a place in the tumor necrosis factor (TNF) superfamily whose interactions play an essential role in causing of different immune system ailments.

Polycystic Kidney Disease (PKD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Polycystic kidney disease (PKD) is a genetic disorder that primarily affects kidneys. It causes fluid-filled cysts to grow inside the kidneys, which increase the size and damage tissues of the kidneys.

Pancreatic Cancer Therapeutics Market to Witness Significant Growth due to Increase in Number of Pancreatic Cancer Cases in the Coming Years

Pancreatic cancer occurs when malignant cells develop in the part of pancreas, resulting in the formation of a tumor. Pancreatic cancer typically spreads rapidly to nearby organs. It is rarely detected in its early stages.

Pancreatic Cancer Incidence to Witness Burgeoning Trends in the Coming Years

Pancreatic cancer is defined as the development of tumor and uncontrolled growth of cells in the pancreas. There are mainly two different types of pancreatic cancer: exocrine and endocrine, depending upon the part of pancreas affected.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics to Witness Significant Growth due to Positive Clinical Results in the Coming Years

COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Factors leading to the occurrence of COPD include smoking, environmental exposures and genetic (inherited) risk.

Positive Clinical Trials are Responsible for the Growth of Dry Eye Syndrome Pipeline

Dry eye syndrome, also known as dry eye disease, keratitis sicca and keratoconjunctivitis sicca, is a form of ocular surface and tears disease that results in problems in vision, discomfort and tear film instability, causing potential damage to the ocular surface.

Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Advanced Regulatory Approaches by the Drug Developers

PSP is identified as a rare brain disorder, which affects the control of eye movement and walking. Individuals with PSP also face difficulty in swallowing, speaking, and controlling other voluntary movements.

Androgenetic Alopecia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth.

Constipation Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Constipation is one of the most common medical condition, characterized by irregular bowel movement. Pain in passing stool, lumpy and hard stool, and feeling of incomplete emptying are some of the most common symptoms of constipation.

Hemochromatosis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Hemochromatosis, also known as iron overload, is identified as increased level of iron in the body. It has symptoms such as joint pain, weight loss, erectile dysfunction in men, and irregular menstrual cycle in women.

Various Advancements in the Drug Development Technologies are Beholding the Growth of Presbyopia Therapeutics Pipeline

Presbyopia is an age-related eye disorder, which affects the near sight vision. Primary cause of the disease is loss of flexibility of eye lenses present in cornea. Due to this, patients face difficulty in day-to-day activities like reading, blurred vision, headaches, and eyestrain.

Graves’ Ophthalmopathy Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Graves’ ophthalmopathy is identified as an autoimmune disease in which the overproduction of thyroid hormones affects ocular and orbital tissues. According to the research studies, this disease is associated with elevated TSH receptor expression in the tissues of the orbit, with increase in the level of TSH receptor antibodies.

Hyperhidrosis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Hyperhidrosis refers to excessive sweating from some body parts, including palms, heads, feet, or underarms. It is mainly categorized into two types: primary hyperhidrosis and secondary hyperhidrosis.

Hyperlipidemia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Hyperlipidemia is unsuitable increase of cholesterol in blood, which can be inherited or acquired. Hypertriglyceridemia, and hypercholesterolemia are the two types of hyperlipidemia.

Hypertrophic Scars Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Hypertrophic scar can be defined as a thickened and raised scar that forms at the site where skin is damaged. A hypertrophic scar is an after effect to an injury.

Interleukin-6 (IL-6) Inhibitors Pipeline to Witness Growth due to Positive Clinical Results in the Coming Years

IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6α receptor.

Japanese Encephalitis (JE) Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Strategic Collaboration Approach by Drug Developers

JE is a viral infection caused by the bite of Culex tritaeniorhynchus mosquito. The prevention from the mosquito bites is the key preventive measure for the disease.

Lysosomal Storage Disorder (LSD) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

LSD refers to a group of genetically inherited disorders, which are characterized by enzyme deficiencies. It results in accumulation of toxic chemical substances in the body’s cells.

Myasthenia Gravis (MG) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

MG is a neuromuscular disorder, which weakens muscles by decreasing number of acetylcholine receptors at the neuromuscular junction. The disease becomes prominent during adulthood; but symptoms can be observed at any age.

Myelofibrosis (MF) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

MF is an uncommon ailment described by the presence of excessive scar tissues in bone marrow that diminishes its hematopoietic potential. MF is the causes of a genetic mutation in the blood stem cells.

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Pipeline to Witness Significant Growth due to Increased Number of Pipeline Candidates by Drug Developers

NF-κB is a family of transcription factors, aiding many regulatory cellular functions such as regulation of apoptosis, inflammatory responses, cellular growth, and others.

Uveitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

Uveitis refers to a group of disorders that lead to inflammation in eyes and damages their tissues. The disease not only affects uvea, which is the middle layer of the eye, but also affects retina, vitreous humor, optic nerve, and iris.

Benign Prostatic Hyperplasia (BPH) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

BPH can be identified as enlargement of prostate gland, a condition affects majority of male population. It is non-cancerous and goes through two main growth periods as a man age.

Bronchiectasis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Bronchiectasis, a chronic airways infection, affects lungs and widens bronchial trees. This leads to gradual loss of mucus clearing ability, which increases growth of bacteria.

Positive Clinical Trials are Responsible for the Growth of Diabetic Foot Ulcer Therapeutics Pipeline

A diabetic foot ulcer is an open sore or wound that occurs in approximately 15% of patients with diabetes and is commonly located in the bottom of the foot.

Janus Kinase (JAK) Inhibitors Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

JAK comprises four receptors JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) which help in cytokine mediated signaling through the JAK/STAT pathway. There are two nearly identical phosphate transferring domains present in JAKs.

Various Advancements in Drug Development Technologies are Beholding the Growth of Restless Legs Syndrome (RLS) Therapeutics Pipeline

RLS is a neurological sleep disorder that causes intense and irresistible urge to move leg. It can occur due to medical problems such as Parkinson’s disease, peripheral neuropathy, diabetes, and iron deficiency, or genetically.

Lennox-Gastaut Syndrome (LGS) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Trial Results in the Coming Years

LGS is a rare and severe form of epilepsy that mostly affects individuals during infancy or early childhood. This syndrome has the tendency to develop between the age of one to eight years in children, and can be characterized by polymorphic seizures and neuropsychological decline.

Rhinovirus Infection Therapeutics to Witness Significant Growth due to Positive Results in the Coming Years

Rhinovirus infections, caused by rhinoviruses, occurs in the upper or lower respiratory tracts. The occurrence frequency of the infection is a year-around, but most often in spring and fall seasons. The infections are mostly acknowledged as ‘common cold’, but the infection can also lead to lesser degree pneumonia, sore throats, sinus infections, ear infections, and bronchiolitis.

Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years

IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens.

Wnt Signaling Pathway Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation.

Akt/Protein Kinase B (PKB) Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

Achondroplasia Therapeutics Pipeline is Witnessing Significant Growth due to Positive Clinical Results

Achondroplasia therapeutics currently exhibits a considerably strong pipeline with seven active drug candidates.